Ready to start planning your care? Call us at 833-347-1665 to make an appointment.
Newsroom
At Memorial Sloan Kettering Cancer Center, our world-renowned scientists are constantly advancing our knowledge about cancer, and our discoveries are improving care for patients here and all over the world. On this page, you will find information about our groundbreaking work and the dedicated professionals who make it all happen.
For Journalists
Connect with us to reach MSK experts for media inquiries and for story ideas.
Memorial Sloan Kettering Cancer Center (MSK) announced that Selwyn M. Vickers, MD, FACS, an internationally recognized pancreatic cancer surgeon and researcher, a pioneer in cancer health disparities research, and an academic medical leader, has assumed the role of its next President and Chief Executive Officer.
Memorial Sloan Kettering Cancer Center (MSK) has been recognized as the number two hospital for cancer care in the nation by U.S. News & World Report in its annual Best Hospitals listing. Since these prestigious rankings were established more than 30 years ago, MSK has consistently ranked among the top two cancer hospitals in the country.
Over the last seven and a half decades, researchers at the Sloan Kettering Institute have made important contributions to the fundamental understanding of human biology, as well as driven practice-changing innovations in the treatment of cancer.
Memorial Sloan Kettering Cancer Center (MSK) today announced that Shelly Anderson, MPM, will join the institution as the inaugural Hospital President on September 25. Anderson joins MSK from Brigham and Women’s Hospital (BWH) in Boston, where she has been a member of the executive leadership team since 2011, most recently serving as Executive Vice President and Chief Operating Officer.
Ingo K. Mellinghoff, MD, FACP, neuro-oncologist and Chair of the Department of Neurology, presented significant results from a phase III trial in patients with residual or recurrent grade 2 glioma with an IDH1/2 mutation.
Deb Schrag, MD, MPH, gastrointestinal oncologist and Chair of the Department of Medicine, presented results from a randomized phase III trial of neoadjuvant chemoradiation versus neoadjuvant FOLFOX chemotherapy with selective use of chemoradiation, followed by total surgical excision for the treatment of patients with locally advanced rectal cancer.
Kieran Healy was feeling worse by the day. A new father at 43 years old, he was bone-tired and losing weight. He had night sweats and a strange lump in his belly. His local hospital in Manhattan ordered an ultrasound and a CT (computed tomography) scan — but they were scheduled over a month away.
MSK has developed an arsenal of tests that are at the front lines of precision treatments. They target the structure of proteins that cause cancer, offering people new hope.
When Dr. Urvi Shah was diagnosed with Hodgkin lymphoma in 2016 during her first year as a hematology-oncology fellow, she heard lots of recommendations from friends and family about what she should and shouldn’t eat.
Learn how a heralded clinical trial at Memorial Sloan Kettering Cancer Center is being expanded that made rectal cancer disappear in every participant using only immunotherapy that targets a rare mutation — without the need for surgery, chemotherapy, or radiation.
MSK-led research could change the practice of medicine for millions of people whose breast cancer has spread. Research led by Dr. Shanu Modi has demonstrated that a targeted drug called trastuzumab deruxtecan blocks the protein HER2 even when its levels are low — the case for about 55% of people with breast cancer.
The protein made by the p53 gene helps guard the body against cancer, in part by detecting and repairing damaged DNA. Over the 30 years since p53 was first discovered, it has remained a stubborn mystery, resisting efforts to tease apart exactly how the loss of the gene’s protection leads to the development of cancer. In August 2022, researchers in the Sloan Kettering Institute were able to provide some new answers that hint at new avenues for treatment.
Cancer Straight Talk brings together national experts and cancer patients to have straightforward, evidence-based conversations. Medical oncologist Diane Reidy-Lagunes hosts this series with the mission of educating and empowering patients to make the right decisions and live happier, healthier lives.
